IMS Health has made its third cloud-based acquisition in as many months, snapping up mobile sales and marketing systems provider 360 Vantage. The deal continues IMS' whirlwind push into the cloud that has also seen it snag Appature and Semantelli in the past few months.
IMS Health has purchased Semantelli, a software startup whose technology reduces the risk of social media engagement for pharma companies. Drugmakers have tiptoed in the wild realm of the social web over fears about regulatory snafus and compliance headaches. Semantelli has helped pharma companies with those worries and has been rewarded.
It's confirmed: Another study shows that U.S. drug spending dropped ever so slightly last year. The obvious culprit is generic drugs, with major blockbusters such as Pfizer's ($PFE) Lipitor and AstraZeneca's ($AZN) Seroquel IR now facing cheap rivals.
Doctors prescribe the "Z-Pak" for everything from ear infections to pneumonia. But the FDA wants to make clear that for a small group of people, there is a better than average chance it will mess with their heart rhythms and possibly kill them.
When is a blockbuster not a blockbuster? When its sales are adjusted for inflation--or for share of the global pharma market. That $1 billion blockbuster threshold might have been a lofty goal in 1987, but in today's dollars, the bar would stand at $1.75 billion, an IMS Health consultant postulates in an article for PharmaPhorum .
One of the hot trends in cancer medication is genetic tests that can tell doctors if a related treatment will work on certain patients.
Turkey's pharma market isn't as high-profile as the oft-celebrated China or India. But that doesn't mean foreign drugmakers aren't looking for ways to beef up their operations in the country.
Benjamin Shobert, founder and managing director of consultancy Rubicon Strategy Group, says there are significant looming questions about whether the Chinese market will pay off in the long run for Big Pharma.
IMS Health has gobbled up DecisionView, a San Francisco-based provider of web-based software that analyzes patient enrollment in clinical trials via an acquisition.
Pharma M&A activity is heating up, particularly among medium-sized companies, and shows signs of accelerating further, MarketWatch reports.